在患病的结肠组织中的eQTL识别了与IBD相关的潜在点基因
Nina C Nishiyama1,2, Sophie Silverstein2,3, Kimberly Darlington2,4
1Curriculum in Bioinformatics and Computational Biology, Department of Genetics, School of Medicine, Department of Biology, College of Arts and Sciences, The University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Nature communications
|February 13, 2026
概括
在炎症性肠病 (IBD) 结肠组织中使用表达量化特征位点 (eQTL) 分析,研究人员确定了108个IBD位点的194个潜在点基因. 患病组织eQTL研究对于了解IBD变体后果至关重要.
科学领域:
- 遗传学 是一个遗传学.
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 全基因组关联研究 (GWAS) 已经确定了300多个与炎症性肠病 (IBD) 相关的位点.
- 这些IBD相关位点所准的特定基因在很大程度上仍未知.
- 了解这些遗传联系对于IBD病变研究至关重要.
研究的目的:
- 通过以疾病为中心的表达量化特征位点 (eQTL) 分析,识别IBD相关位点的潜在目标基因.
- 调查使用IBD患者结肠组织是否可以揭示非IBD队列中错过的调节变异.
- 探索疾病状态对监管环境的影响及其与IBD风险变异的关联.
主要方法:
- 对252名IBD患者的结肠组织样本进行了以疾病为中心的eQTL分析.
- 将IBD结肠组织的eQTL数据与非IBD结肠组织的数据进行比较.
- 分析了eQTL结果以与IBD GWAS同位体进行丰富,并确定了潜在的目标基因.
主要成果:
- 通过整合IBD和非IBD结肠组织的eQTL数据,确定了108个IBD位点的194个潜在点基因.
- 观察到IBD GWAS局部化IBD组织中的eQTL的丰富.
- 提供了 ABO 和 TNFRSF14 等特定基因的证据,并发现了与仅使用非IBD 组织的分析相比,更多的潜在点基因.
- 发现疾病状态可能会改变监管格局,可能增加eQTL效应大小.
结论:
- 在IBD结肠组织中对特定疾病的eQTL分析对于识别IBD相关变异的基因有价值.
- 疾病状态可以改变监管格局,影响遗传变异的影响.
- 这些发现强调了研究患病组织的重要性,以充分了解IBD相关遗传位点的功能后果.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
532
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
532
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
561
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
561
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
598
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
598
The Colonization of Land
37.9K
Changes in the environment of the early Earth drove the evolution of organisms. As prokaryotic organisms in the oceans began to photosynthesize, they produced oxygen. Eventually, oxygen saturated the oceans and entered the air, resulting in an increase in atmospheric oxygen concentration, known as the oxygen revolution approximately 2.3 billion years ago. Therefore, organisms that could use oxygen for cellular respiration had an advantage. More than 1.5 years ago, eukaryotic cells and...
37.9K
Drugs for Treatment of Ulcerative Colitis in IBD
541
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
541
Gene Therapy
27.7K
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be...
27.7K


